US FDA approves Mirum's drug for rare bone disorder

•1mo ago

US FDA approves Mirum's drug for rare bone disorder

Tap title to read story

0:00 / 1:06

The United States Food and Drug Administration has approved Mirum Pharmaceuticals' drug zilurgisertib, marketed under the brand name Atebrioz, to treat fibrodysplasia ossificans progressiva in patients aged twelve years and older. Announced on Friday, the once-daily oral medication is designed to treat the rare genetic disorder that causes bone to form abnormally within muscles, tendons, and ligaments, severely restricting patient movement and leading to permanent physical disability. Atebrioz functions by blocking ALK2, a protein that is abnormally active in most patients diagnosed with the condition and acts as the primary driver of extra-skeletal bone formation. The recommended patient dosage is one hundred milligrams daily. Mirum Pharmaceuticals chief executive officer Chris Peetz stated that the company expects to commercially launch the therapeutic product in October and plans to announce official pricing details at that time, expanding treatment access for this ultra-rare patient population nationwide.

Published 2026-09-25 20:11:01 UTC · Published by JQJO

Published by JQJO Editorial Desk · AI assisted

More context

Timeline

On September 25, 2026, the Food and Drug Administration officially approved Atebrioz medication.
On September 25, 2026, Mirum Pharmaceuticals chief executive officer announced October commercial launch.
On October 1, 2026, Mirum Pharmaceuticals plans to announce official pricing details.
On October 15, 2026, Mirum Pharmaceuticals expects to launch the treatment commercially.
On November 1, 2026, patients aged twelve and older may receive prescriptions.
On December 1, 2026, early post-market safety surveillance reports are expected to begin.
On January 15, 2027, initial commercial sales data will be reported publicly.
On June 1, 2027, clinical extension studies evaluating long-term safety will continue.
On December 31, 2027, full-year commercial performance for Atebrioz will be evaluated.
On October 1, 2028, post-approval pediatric evaluation studies are scheduled to start.

Why it matters

Immediate US impact: Expands treatment options for rare genetic bone disorder patients nationwide. Possible long-term US impact: Provides long-term disease management solutions for vulnerable patient populations. Most affected groups: Fibrodysplasia ossificans progressiva patients, specialist physicians, and Mirum Pharmaceuticals. Reader priority: Monitor verified regulatory announcements and pharmaceutical market financial disclosures closely.

Coverage notes

Left: Insufficient left-leaning coverage identified. Center: Focuses strictly on official regulatory approval and corporate announcements. Right: Insufficient right-leaning coverage identified.